According to the World Health Organization (WHO), chronic obstructive pulmonary disease (COPD) is the third leading cause of ...

Bronchiectasis is one of the most neglected chronic lung diseases despite the fact it impacts 300,000 people in the UK ...

COPD, or chronic obstructive pulmonary disease, affects more than 30 million Americans, yet many have never heard of it. COPD ...

Lung conditions, like asthma and chronic obstructive pulmonary disease, are more common in women than men. Stephanie Harris ...

Pharmaceutical giant Merck is buying Verona Pharma, a company that focuses on respiratory diseases, in an approximately $10 ...

Dietary approaches are shaping up as a key aspect of chronic obstructive pulmonary disease (COPD) management.

Dupilumab reduces COPD exacerbations and Type 2 inflammation biomarkers, with strongest benefit in patients with high ...

Interstitial lung abnormalities (ILAs) are parenchymal lung changes found on high-resolution CT. In routine use of high-resolution CT, non-specific findings are frequently reported, which has prompted ...

Synchrony Medical announced that it received FDA 510 (k) clearance for its LibAirty airway clearance system.

The National Lung Health Alliance (NLHA) is Canada’s leading advocacy network for lung health. Led by the Lung Health Foundation, the alliance includes several organizations: BC Lung Foundation, ...

Global Phase 2 clinical trial, VENTURE, to evaluate the efficacy and safety of verekitug administered every 12 or 24 weeks in moderate-to-severe COPD - - Broadens global development program for vereki ...

Verona Pharma’s flagship drug last year became the first new maintenance treatment for chronic obstructive pulmonary disease ...